Clinical trial
Safety and Efficacy of Recombinant Human Platelet-Activating Factor…
NCT00037687 · ICOS Corporation, Industry · Terminated
Key facts
| NCT number | NCT00037687 |
|---|---|
| Title | Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis |
| Official title | A Phase 3 Study to Demonstrate the Safety and Efficacy of Recombinant Platelet-Activating Factor Acetylhydrolase (rPAF-AH, Pafase®) for Reducing 28 Day All Cause Mortality in Patients With Severe Sepsis |
| Lead sponsor | ICOS Corporation, Industry |
| Collaborators | Suntory Pharmaceutical Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sepsis |
| Intervention type | Drug |
| Interventions | rPAF-AH |
| Enrollment | 2,500 |
| Start date | Apr 1, 2001 |
| Completion | Dec 1, 2004 |
| First posted | May 21, 2002 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: